Trial ChiCTR-OPN-20000
Publication Cao Y, J Allergy Clin Immunol, 2020
Primary outcome on the report: The primary efficacy end point was the time to clinical improvement, defined as the time from randomization (D0) to an improvement of two points on a seven-category ordinal scale or live discharge from the hospital (Dend) and improvement rate of follow-up CT scans at D14.